{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:41:41Z","timestamp":1766050901710,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lung adenocarcinoma with a micropapillary component (LMPC) is an aggressive histologic subtype of lung cancer characterized by unique pathological features and poor prognosis. While previous studies have identified driver mutations in LMPC, its comprehensive molecular profile and prognosis-related biomarkers in the Chinese population remain poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study of 54 stage I-III LMPC patients who underwent complete resection. Tumor samples from these patients were analyzed using broad-panel next-generation sequencing of 425 cancer-related genes. We explored the associations among clinicopathologic factors, genomic characteristics, and post-operative recurrence risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to a reference cohort of 113 LADC patients, LMPC exhibited a distinct genetic profile, with a greater diversity of targetable mutations, an increased number of oncogenic pathway alterations (NPA), and more oncogenic pathway-related alterations. The mutation frequencies of <jats:italic>ERBB4<\/jats:italic> (11.1% vs. 1.8%, P=0.015), <jats:italic>BRAF<\/jats:italic> (9.3% vs. 1.8%, P=0.037), <jats:italic>PIK3CA<\/jats:italic> (14.8% vs. 4.4%, P=0.029), <jats:italic>RPTOR<\/jats:italic> (P=0.033), and <jats:italic>NOTCH2<\/jats:italic> (P=0.033) were significantly higher in LMPC. Additionally, LMPC patients had significantly more alterations in three oncogenic pathways (PI3K, Wnt, and TGF-\u03b2) and a significantly increased NPA (P&amp;lt;0.001). In stage II-III LMPC patients, <jats:italic>SMARCA4<\/jats:italic> mutations (13.9 months vs. not reached (NR), P=0.013) and alterations in the SWI\/SNF (16.3 months vs. NR, P=0.003) and Nrf2 (17.0 months vs. NR, P=0.046) pathways were significantly associated with higher postoperative recurrence risk. Furthermore, tumor mutation burden (TMB) was significantly correlated with postoperative disease-free survival (DFS), with patients having low TMB showing prolonged median DFS compared to those with high TMB (NR vs. 16.8 months, P=0.021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study elucidates the unique genetic landscape of Chinese resectable LMPC patients and highlights high TMB and mutations in <jats:italic>SMARCA4<\/jats:italic>, SWI\/SNF, and Nrf2 pathways as potential prognostic indicators in stage II-III disease. As these factors were not confirmed in multivariate models, they should be validated in larger, multi-center cohorts to guide future risk stratification and treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1574817","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:39Z","timestamp":1748491959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiafu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuane","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182828fb8","article-title":"Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC\/ATS\/ERS lung adenocarcinoma classification in stage III (N2) patients","volume":"8","author":"Russell","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201107-042ST","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary","volume":"8","author":"Travis","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/his.14918","article-title":"Deep learning-based classification and spatial prognosis risk score on whole-slide images of lung adenocarcinoma","volume":"83","author":"Ding","year":"2023","journal-title":"Histopathology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34163","article-title":"Deep-learning-based 3D super-resolution CT radiomics model: Predict the possibility of the micropapillary\/solid component of lung adenocarcinoma","volume":"10","author":"Xing","year":"2024","journal-title":"Heliyon"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-544","article-title":"Predicting prognosis in patients with stage IA lung adenocarcinoma with a micropapillary component using a nomogram based on computed tomography radiomics and clinicopathologic factors: a retrospective analysis","volume":"13","author":"Li","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000530528","article-title":"Predictive value of recurrence of solid and micropapillary subtypes in lung adenocarcinoma","volume":"102","author":"Motono","year":"2024","journal-title":"Oncology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13019-020-01199-8","article-title":"Both the presence of a micropapillary component and the micropapillary predominant subtype predict poor prognosis after lung adenocarcinoma resection: a meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"J Cardiothorac Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezaa138","article-title":"Impact of the micropapillary component on the timing of recurrence in patients with resected lung adenocarcinoma","volume":"58","author":"Watanabe","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-5043-9","article-title":"Minor components of micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis","volume":"23","author":"Zhao","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.014","article-title":"The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma","volume":"11","author":"Yanagawa","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0274-7","article-title":"Clinicopathological significance of micropapillary pattern in lung adenocarcinoma","volume":"24","author":"Pyo","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000341","article-title":"A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component","volume":"9","author":"Zhang","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/path.6416","article-title":"Multi-omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I-III micropapillary lung adenocarcinoma","volume":"266","author":"Qu","year":"2025","journal-title":"J Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.08.64","article-title":"Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma","volume":"10","author":"Ma","year":"2018","journal-title":"J Thorac Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.652193","article-title":"Integrated analysis of genomic and immunological features in lung adenocarcinoma with micropapillary component","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.011","article-title":"The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer","volume":"12","author":"Chansky","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0585","article-title":"Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer","volume":"25","author":"Fang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.11.008","article-title":"Driver mutation profiles and clinicopathological correlation in pulmonary adenocarcinoma with a micropapillary component","volume":"85","author":"Zhang","year":"2019","journal-title":"Hum Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.005","article-title":"The underlying tumor genomics of predominant histologic subtypes in lung adenocarcinoma","volume":"15","author":"Caso","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and other SWItch\/sucrose nonFermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12831","article-title":"SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis","volume":"15","author":"Liu","year":"2021","journal-title":"Mol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670040","article-title":"ARID1A, ARID1B, and ARID2 mutations serve as potential biomarkers for immune checkpoint blockade in patients with non-small cell lung cancer","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implications of KEAP1-NFE2L2 mutations in NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.07.006","article-title":"KEAP1\/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype","volume":"159","author":"Dempke","year":"2021","journal-title":"Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659200","article-title":"KEAP1\/NFE2L2 mutations of liquid biopsy as prognostic biomarkers in patients with advanced non-small cell lung cancer: results from two multicenter, randomized clinical trials","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.05.004","article-title":"High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study","volume":"22","author":"Talvitie","year":"2020","journal-title":"Neoplasia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","article-title":"Tumor mutation burden as a biomarker in resected non-small-cell lung cancer","volume":"36","author":"Devarakonda","year":"2018","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174251","article-title":"Molecular subtyping and prognostic assessment based on tumor mutation burden in patients with lung adenocarcinomas","volume":"20","author":"Wang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.003","article-title":"Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: brief report","volume":"13","author":"Owada-Ozaki","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.2023.28.4.175","article-title":"Prognostic significance of tumor mutation burden among patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy: an exploratory study","volume":"28","author":"Shen","year":"2023","journal-title":"J Cancer Prev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3892\/br.2018.1143","article-title":"Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker","volume":"9","author":"Barrera-Rodr\u00edguez","year":"2018","journal-title":"BioMed Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/583929","article-title":"TP53 mutations in nonsmall cell lung cancer","volume":"2011","author":"Mogi","year":"2011","journal-title":"J BioMed Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070684","article-title":"A critical review of the impact of SMARCA4 mutations on survival outcomes in non-small cell lung cancer","volume":"14","author":"Manolakos","year":"2024","journal-title":"J Pers Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1574817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:40Z","timestamp":1748491960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1574817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1574817"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1574817","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"1574817"}}